Dr Reddy’s Laboratories has launched nitroglycerin sublingual tablets, a therapeutic equivalent generic version of Nitrostat (Nitroglycerin) sublingual tablets in the US.

The drug is used for prevention or reliving a sudden attack of angina (chest pain) caused by heart disease had been approved by the United States Food and Drug Administration (USFDA).

The company has said in a statement that Nitrostat (Nitroglycerin) sublingual tablet brand had the US sales of about USD 108 million for the most recent 12 months ending in March 2016 (according to IMS Health data).

Read EquityPandit’s Nifty Pharma Outlook for this week